Chemoreduction for retinoblatoma. Analyi of tumor control and rik for recurrence in 457 tumor

Purpoe To evaluate retinoblatoma control following chemoreduction. Deign Interventional cae erie. Method Propective. etting ingle center trial. Patient population 457 retinoblatoma in 193 eye of 125 patient. Nonrandomized, noncomparative tudy. Intervention All patient received intravenou vincritine, etopoide, and carboplatin,. The tumor were managed with chemoreduction alone (group W) or chemoreduction combined with thermotherapy (group X), cryotherapy (group Y), or both thermotherapy and cryotherapy (group Z). Main outcome meaure Tumor recurrence in each treatment group. Reult Of 457 retinoblatoma, 63 (14%) were in group W, 256 (56%) in group X, 127 (28%) in group Y, and 11 (2%) in group Z. The tumor wa located in the macula in 33 (52%) of group W, 109 (43%) of group X, 3 (2%) of group Y, and 9 (1%) of group Z. The mean tumor thickne at initial examination wa 7 mm for group W, 4 mm for group X, 2 mm for group Y, and 3 mm for group Z. Uing Kaplan-Meier etimate, recur-rence of the individual retinoblatoma at 7 year wa found in 45% of group W and 18% for combined group X, Y, and Z. Rik factor predictive of tumor recurrence by multivariate analyi included macular tumor location for all group and additionally female gender for group W and increaing tumor thickne for group X, Y, and Z. Concluion Chemoreduction alone or combined with cryotherapy or thermotherapy i effective for treatment of retinoblatoma, but tumor recurrence rate i highet for thoe located in the macula and thoe with greater thickne.